Adrian Gottschalk, President and CEO of Foghorn Therapeutics, describes the therapeutic potential within and beyond oncology of the chromatin regulatory system — an area of biology that had been previously unexplored in drug development. More from Flagship @ JPM2023 here.
Related Companies
- Foghorn Therapeutics Founded: 2016
